Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 1 12Phase 3 5Phase 1/2 2Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 23Metformin 14pembrolizumab 12Radiotherapy 12Biopsy 11Nivolumab 9Fluorouracil 9Cyclophosphamide 9Temozolomide 7Radiation 7Bevacizumab 7gallium 68 PSMA-11 6Sirolimus 6Rituximab 6Letrozole 6Etoposide 6Cisplatin 6Aspirin 6olaparib 5Surveys and Questionnaires 5Radiosurgery 5Oxaliplatin 5Irinotecan 5Indocyanine Green 5Granulocyte Colony-Stimulating Factor 5Fluorodeoxyglucose F18 5Dexamethasone 5aldesleukin 4Surgical Procedures, Operative 4Proflavine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Completed × rucaparib × Clear all
NCT03911453 2024-10-03

Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors

University of Arizona

Phase EARLY_PHASE1 Completed
20 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡